• Cohort 1: ORR in patients with PD-L1 positive status [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 1: PFS in patients with PD-L1 positive status [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 2: ORR in patients with HR-positive, HER2-negative disease [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 2: PFS in patients with HR-positive, HER2-negative disease [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 3: ORR in patients with HR-positive, HER2-negative disease [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 3: PFS in patients with HR-positive, HER2-negative disease [ Time Frame: Approximately 2.0-3.0 years ]

• Cohort 1: ORR [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 1: PFS [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 2: ORR [ Time Frame: Approximately 2.0-3.0 years ]

• Cohort 1: ORR in all patients [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 1: PFS in all patients [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 1: DoR [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 1: OS [ Time Frame: Approximately 4.0-5.0 years ]
• Cohort 2: ORR in patients with triple-negative disease [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 2: PFS in patients with triple-negative disease [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 2: DoR [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 2: OS [ Time Frame: Approximately 4.0-5.0 years ]
• Cohort 3: ORR in patients with triple-negative disease [ Time Frame: Approximately 1.0-2.0 years ]
• Cohort 3: PFS in patients with triple-negative disease [ Time Frame: Approximately 1.5-2.5 years ]
• Cohort 3: DoR [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 3: OS [ Time Frame: Approximately 4.0-5.0 years ]

• Cohort 1: DoR [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 1: OS [ Time Frame: Approximately 4.0-5.0 years ]
• Cohort 2: PFS [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 2: DoR [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 2: OS [ Time Frame: Approximately 4.0-5.0 years ]

• Cohort 1: ORR by level of PD-L1 expression as determined by central PD-L1 testing [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 1: PFS by level of PD-L1 expression as determined by central PD-L1 testing [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 1: Central nervous system (CNS) ORR in patients with CNS metastases at baseline [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 1: CNS DoR in patients with CNS metastases at baseline [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 2: CNS ORR in patients with CNS metastases at baseline [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 2: CNS DoR in patients with CNS metastases at baseline [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 3: CNS ORR in patients with CNS metastases at baseline [ Time Frame: Approximately 1.0-2.0 years ]
• Cohort 3: CNS DoR in patients with CNS metastases at baseline [ Time Frame: Approximately 1.5-2.5 years ]

• Cohort 1: ORR by PD-L1 expression [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 1: PFS by PD-L1 expression [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 1: CNS ORR in patients with CNS metastases at baseline [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 1: CNS DoR in patients with CNS metastases at baseline [ Time Frame: Approximately 2.5-3.5 years ]
• Cohort 2: ORR by receptor subtype for the hormone receptor (HR) positive and triple-negative subgroups [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 2: CNS ORR in patients with CNS metastases at baseline [ Time Frame: Approximately 2.0-3.0 years ]
• Cohort 2: CNS DoR in patients with CNS metastases at baseline [ Time Frame: Approximately 2.5-3.5 years ]

CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with MBC.

Cohort 1:

Approximately 200 patients with triple-negative MBC who have not received prior chemotherapy for advanced disease will be randomized 1:1:1 to receive tesetaxel dosed orally at 27 mg/m2 once every three weeks (Q3W) plus either:

• Nivolumab at 360 mg by intravenous infusion Q3W;
• Pembrolizumab at 200 mg by intravenous infusion Q3W; or
• Atezolizumab at 1,200 mg by intravenous infusion Q3W.

Nivolumab and pembrolizumab (programmed cell death protein 1 [PD-1] inhibitors) and atezolizumab (a programmed death-ligand 1 [PD-L1] inhibitor) are immuno-oncology (IO) agents approved for the treatment of multiple types of cancer. Two of these agents, atezolizumab and pembrolizumab, have been approved by the U.S. Food and Drug Administration (FDA) as a first-line treatment for patients with triple-negative MBC. The primary efficacy endpoints for Cohort 1 are ORR and PFS in patients with PD-L1 positive status. The secondary efficacy endpoints are ORR and PFS in all patients, duration of response (DoR) and overall survival (OS).

Cohort 2:

Approximately 60 elderly patients with HER2-negative MBC who have not received prior chemotherapy for advanced disease will receive tesetaxel monotherapy dosed orally at 27 mg/m2 Q3W. The primary efficacy endpoints for Cohort 2 are ORR and PFS in patients with HR-positive, HER2-negative disease. The secondary efficacy endpoints are ORR and PFS in patients with triple-negative disease, DoR and OS.

Cohort 3:

Approximately 60 non-elderly adult patients with HER2-negative MBC who have not received prior chemotherapy for advanced disease will receive tesetaxel monotherapy dosed orally at 27 mg/m2 Q3W. The primary efficacy endpoints for Cohort 3 are ORR and PFS in patients with HR positive, HER2-negative disease. The secondary efficacy endpoints are ORR and PFS in patients with triple negative disease, DoR and OS.

• Drug: Tesetaxel
  Tesetaxel at 27 mg/m2 orally Q3W
• Drug: Nivolumab
  Nivolumab at 360 mg by intravenous infusion Q3W
• Drug: Pembrolizumab
  Pembrolizumab at 200 mg by intravenous infusion Q3W
• Drug: Atezolizumab
  Atezolizumab at 1,200 mg by intravenous infusion Q3W

• Experimental: Cohort 1, Arm A: Tesetaxel plus nivolumab
  Interventions:

  • Drug: Tesetaxel
  • Drug: Nivolumab
• Experimental: Cohort 1, Arm B: Tesetaxel plus pembrolizumab
  Interventions:

  • Drug: Tesetaxel
  • Drug: Pembrolizumab
• Experimental: Cohort 1, Arm C: Tesetaxel plus atezolizumab
  Interventions:

  • Drug: Tesetaxel
  • Drug: Atezolizumab
• Experimental: Cohort 2: Tesetaxel
  Intervention: Drug: Tesetaxel
• Experimental: Cohort 3: Tesetaxel
  Intervention: Drug: Tesetaxel

Inclusion Criteria:

• Female or male patients aged:

  • Cohort 1: ≥ 18 years old
  • Cohort 2: ≥ 65 years old
  • Cohort 3: ≥ 18 to < 65 years old
• Histologically or cytologically confirmed breast cancer
• Most recent biopsy must be HER2-negative
• Cohort 1 only: Most recent biopsy must be hormone receptor (HR) (estrogen receptor and progesterone receptor) negative

• Measurable disease per RECIST 1.1.

  • Patients with bone-only metastatic cancer must have a measurable lytic or mixed lytic-blastic lesion
  • Known metastases to the CNS are permitted but not required
• Documented (including de novo): (a) locally advanced breast cancer that is not considered curable by surgery and/or radiation; or (b) metastatic breast cancer
• Disease-free interval of at least 12 months after the completion of systemic neoadjuvant or adjuvant chemotherapy for patients previously treated with systemic chemotherapy for a tumor surgically resected with curative intent
• Cohorts 2 and 3 only: Prior endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor unless endocrine therapy is not indicated. Any prior targeted therapies are permitted. There is no limit to the number of prior endocrine therapies.
• Cohort 1 only: At Screening, patients must have documented evidence of positive PD-L1 expression as assessed via immunohistochemistry (IHC) scoring by local, regional, or central laboratory testing
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
• Adequate bone marrow, hepatic and renal function

Exclusion Criteria:

• Prior chemotherapy for locally advanced or metastatic disease
• Cohort 1 only: prior treatment with pembrolizumab, nivolumab, atezolizumab, any other PD-(L)1/PD-L2 inhibitor or a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor
• Current evidence or history of leptomeningeal disease
• Known human immunodeficiency virus infection, unless well controlled
• Known active hepatitis B or known active hepatitis C infection
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with Study participation or investigational product administration or may interfere with the interpretation of Study results
• Presence of neuropathy Grade > 1
• History of hypersensitivity to any of the Study drugs or any of their ingredients, as applicable

• Cohort 1 only:

  • Chronic autoimmune disease
  • Evidence of active, non-infectious pneumonia (eg, pneumonia due to autoimmune or connective tissue disease)
  • Treatment with a live vaccine within 30 days prior to the first dose of nivolumab, pembrolizumab or atezolizumab
  • History of active tuberculosis
  • Prior organ transplantation including allogeneic stem cell transplantation
  • Active infection requiring systemic therapy
  • Current or prior use of immunosuppressive medication within 7 days prior to Cycle 1, Day 1
  • Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
• Anticancer treatment, including endocrine therapy, radiotherapy (except stereotactic brain radiosurgery), chemotherapy or biologic therapy, ≤ 14 days prior to Enrollment
• Major surgery ≤ 28 days prior to Enrollment
• Less than 2 weeks or 5 plasma half-lives (whichever is greater) since last use of a medication or ingestion of an agent, beverage or food that is a known clinically relevant strong inhibitor or known clinically relevant inducer of the cytochrome P450 (CYP) 3A pathway